Fig. 1. Cytochalasin Z11 (CytoZ11) inhibited RANKL-induced osteoclastogenesis in vitro dose-dependently. (A) Typical images of osteoclastogenesis in the presence of the different doses of CytoZ11 for 5 days. Cells were then proceeded to fixation and subsequent TRAcP staining. (B) Quantification of TRAcP-positive, multinucleated cells (nuclei > 3) (n = 3 per group). (C) The viability of BMMs following 48 hour treatment of CytoZ11 was measured using MTS assay. **p < 0.01 relative to RANKL-induced control group. Scale bar = 200 μm. MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; TRAcP: tartrate resistant acid phosphatase; RANKL: receptor activator of nuclear factor-κB ligand.